Abstracts tagged "biomarkers and spondylarthritis"

Abstract Number: 1663 • 2016 ACR/ARHP Annual Meeting
Assessment of Serum Calprotectin and Osteoprotegerin Levels in a Cohort of Spanish Patients with Axial Spondyloarthritis
Fernanda Genre¹, Carlos Fernández-Díaz¹, Javier Rueda-Gotor¹, Raquel López-Mejías¹, Sara Remuzgo-Martínez¹, Begoña Ubilla¹, Veronica Mijares¹, Alfonso Corrales¹, Virginia Portilla¹, Patricia Fuentevilla¹, Luis Rodriguez-Rodriguez², Ricardo Blanco¹, José Luis Hernandez³ and Miguel Angel Gonzalez-Gay^1,4,5, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ²Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ³Bone Metabolism Unit, Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, RETICEF, Santander, Spain, ⁴School of Medicine, University of Cantabria, Santander, Spain, ⁵Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Calprotectin is a protein involved in several cellular processes including immunomodulation1. Elevated levels of this protein have been observed in inflammatory diseases, since it…
Abstract Number: 2718 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of the M2 Macrophage Markers, CD163 and CD206, Changes Reversely and Soluble CD163 Is Associated with Disease Activity in Spondyloarthritis
Line Dam Heftdal^1,2, René Østgård^3,4, Malene Hvid^3,5, Bent Deleuran^2,3,5, Holger Jon Møller⁵ and Stinne Greisen^2,3, ¹Department of Biomedicine, Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁴Department of Rheumatology, Regional Hospital Silkeborg, Silkeborg, Denmark, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: Spondyloarthritis (SpA) covers a group of interrelated auto-inflammatory disorders where TNFa is a central mediator of disease. T cells and macrophages are abundant in…
Abstract Number: 576 • 2014 ACR/ARHP Annual Meeting
Dikkopf-1 (Dkk-1) Serum Levels in Axial Spondyloarthritis (axSpA) Are Related to Disease Duration
Victoria Navarro-Compán¹, Enrique Melguizo-Madrid², Concepción González-Rodríguez³, Federico Navarro-Sarabia⁴ and Rafael Ariza-Ariza⁴, ¹Rheumatology, University Hospital La Paz and Leiden University Medical Center, Madrid, Spain, ²Biochemistry, University Hospital Virgen Macarena, Sevilla, Spain, ³University Hospital Virgen Macarena, Sevilla, Spain, ⁴Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain

Background/Purpose: Tumor necrosis factor (TNF) alpha is responsible for induction of dkk-1 which down-regulates bone formation. Therefore, it was expected that TNF-blocker therapy would inhibit…
Abstract Number: 555 • 2014 ACR/ARHP Annual Meeting
Urinary Excretion of Type II Collagen C-Telopeptide and Glucosyl-Galactosyl-Pyridinoline As Prognostic Biomarkers in Early Spondyloarthritis
Elisa Trujillo¹ and Maria del Mar Trujillo², ¹Servicio de Reumatologia, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ²Servicio de evaluacion y planificacion, Servicio Canario de la Salud, Tenerife, Spain
Background/Purpose: The search for biomarkers in spondyloarthritis (SpA) is of great interest because of their diagnostic and prognostic role in the treatment of these diseases.…
Abstract Number: 936 • 2013 ACR/ARHP Annual Meeting
Decreased Plasma Levels Of Soluble CD18 Link Leukocyte Migration and Disease Activity In Spondyloarthritis
Tue W. Kragstrup^1,2, Babak Jalilian¹, Malene Hvid³, René Østgård⁴, Berit Schiøttz-Christensen⁵, Anne G. Jurik⁶, William H. Robinson², Thomas Vorup-Jensen¹ and Bent Deleuran^1,7, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁴Dept. of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Aarhus Rheumatology Clinic, Private practice, Aarhus, Denmark, ⁶Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Spondyloarthritis (SpA) comprise a group of diseases characterized by inflammation of the entheses and joints of the axial skeleton primarily driven by innate immune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].